Lenalidomide is active for extramedullary disease in refractory multiple myeloma

被引：14
作者：
Nakazato, Tomonori [1 ]
Mihara, Ai [1 ]
Ito, Chisako [1 ]
Sanada, Yukinari [1 ]
Aisa, Yoshinobu [1 ]
机构：
[1] Yokohama Municipal Citizens Hosp, Dept Hematol, Hodogaya Ku, Yokohama, Kanagawa 2408555, Japan
来源：
ANNALS OF HEMATOLOGY | 2012年 / 91卷 / 03期
关键词：
THALIDOMIDE; BORTEZOMIB;
D O I：
10.1007/s00277-011-1272-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：473 / 474
页数：2
相关论文
共 50 条
  • [41] Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma
    Kauer, Joseph
    Sester, Lilli Sophie
    Kriegsmann, Katharina
    Weinhold, Niels
    Ober, Michael
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Raab, Marc-Steffen
    Sauer, Sandra
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (03) : 453 - 462
  • [42] Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Kraftson, Stephanie
    Ross, Charles W.
    Harvey, Colleen
    Hideshima, Teru
    Sportelli, Peter
    Poradosu, Enrique
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (04) : 472 - 480
  • [43] Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
    Wong, Xin Yi
    Chng, Wee Joo
    Aziz, Mohamed Ismail Abdul
    Ng, Kwong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (02) : 207 - 215
  • [44] Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Siegel, David S.
    Dimopoulos, Meletios A.
    Ludwig, Heinz
    Facon, Thierry
    Goldschmidt, Hartmut
    Jakubowiak, Andrzej
    San-Miguel, Jesus
    Obreja, Mihaela
    Blaedel, Julie
    Stewart, A. Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 728 - +
  • [45] A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
    Berenson, J. R.
    Yellin, O.
    Kazamel, T.
    Hilger, J. D.
    Chen, C-S
    Cartmell, A.
    Woliver, T.
    Flam, M.
    Bravin, E.
    Nassir, Y.
    Vescio, R.
    Swift, R. A.
    LEUKEMIA, 2012, 26 (07) : 1675 - 1680
  • [46] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Totani, Haruhito
    Ri, Masaki
    Kato, Chie
    Nakashima, Takahiro
    Suzuki, Nana
    Hagiwara, Shinya
    Kanamori, Takashi
    Murakami, Satsuki
    Masuda, Arisa
    Kinoshita, Shiori
    Yoshida, Takashi
    Narita, Tomoko
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (03) : 316 - 321
  • [47] Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Tiedemann, Rodger
    Kukreti, Vishal
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 555 - 560
  • [48] Genetic Abnormalities in Extramedullary Multiple Myeloma
    McAvera, Roisin
    Quinn, John
    Murphy, Philip
    Glavey, Siobhan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [49] Lenalidomide in multiple myeloma: current experimental and clinical data
    Cives, Mauro
    Milano, Annalisa
    Dammacco, Franco
    Silvestris, Franco
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 88 (04) : 279 - 291
  • [50] Thalidomide and lenalidomide in the treatment of multiple myeloma
    Kumar, Shaji
    Rajkumar, S. Vincent
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (11) : 1612 - 1622
12345